Quartet Medicine Raises $6.25M; Closes $23.25M Series A Funding

quartet_medicine_logoQuartet Medicine, a Cambridge, MA-based biotechnology company, closed an additional $6.25m finalizing its Series A funding at a total of $23.25 million.

The closing brought in three new investors including Remeditex Ventures and two undisclosed Shanghai-based strategic investors. Series A investors also include Atlas Venture, Novartis Venture Funds, Partners Innovation Fund, and Pfizer Venture Investments. In conjunction with the funding, John Creecy, Chief Executive Officer of Remeditex, joined Quartet’s Board of Directors along with independent member Mark Corrigan, M.D.

The company plans to use the funding to advance its lead program focused on modulating tetrahydrobiopterin (BH4) through early clinical testing over the next two years.

Founded by scientists at Boston Children’s Hospital and École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland in conjunction with Atlas Venture and led by Kevin Pojasek, Ph.D., President and acting Chief Executive Officer, Quartet Medicine focuses on discovering and developing novel treatments for chronic pain and inflammation.
The company is using human genetic and BH4-based biomarker tools, along with preclinical disease models, to select the ideal early clinical proof-of-concept indications for a modulator of the BH4 synthesis pathway. In addition, it is enabling a translational biomarker strategy for clearly establishing human target engagement early in phase 1 clinical trials. This dual indication discovery and translational biomarker-based approach will help de-risk Quartet’s lead program as it advances through early clinical development.

FinSMEs

07/10/2015

Join the discussion